Recently, Hengrui Pharmaceutical and its subsidiary Suzhou Shengdia Biomedical Co., Ltd. received a notice from the State Drug Administration to approve the company's self-developed multi-target tyrosine kinase receptor inhibitor Abbott® combined with the PD-1 inhibitor Erica® for first-line treatment of patients with recurrent or metastatic cervical cancer with fully verified testing methods to evaluate positive PD-L1 expression (≥1). At this point, this target-free combination therapy has officially completed the upgrade of the layout from second-line treatment to first-line treatment for advanced cervical cancer.

Recently, Hengrui Pharmaceutical and its subsidiary Suzhou Shengdia Biomedical Co., Ltd. received a notice from the State Drug Administration to approve the company's self-developed multi-target tyrosine kinase receptor inhibitor Abbott® combined with the PD-1 inhibitor Erica® for first-line treatment of patients with recurrent or metastatic cervical cancer with fully verified testing methods to evaluate positive PD-L1 expression (≥1). At this point, this target-free combination therapy has officially completed the upgrade of the layout from second-line treatment to first-line treatment for advanced cervical cancer.